Health and Healthcare
Bioject's Needle-Free Delivery Technology Used by NIH
Published:
From BioHealth Investor
Bioject Medical Technologies Inc (BJCT) announced early Thursday that the National Institutues of Health (NIH) has initiated its DNA vaccine study to prevent the H5N1 flu virus using the company’s needl-free technology, Biojector 2000 (B2000).
The study aims to use the B2000 to deliver an experimental vaccine by a high pressure liquid forced through the skin, thus ensuring the comfort and safety of the test subjects and investigators.
45 total volunteers will take part in the study, 30 of whom will receive the vaccine, while the rest will receive a placebo injection.
Bioject is a very tiny company, worth slightly less than $15 on the market. It caries about $3 million in cash, and carries debts of about $900 thousand.
Revenues have been increasing steadily over the last few years, but the company’s bottom line has yet to catch up.
Shares of Bioject closed at a penny above $1 on Wednesday, with a 52-week range of $0.72 to $2.
http://www.biohealthinvestor.com/
Sponsored: Want to Retire Early? Start Here
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
